Literature DB >> 15108879

Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients.

Peter G Cordeiro1, Andrea L Pusic, Joseph J Disa, Beryl McCormick, Kimberly VanZee.   

Abstract

Chest wall irradiation is becoming increasingly common for mastectomy patients who have opted for immediate breast reconstruction with tissue expanders and implants. The optimal approach for such patients has not yet been defined. This study assesses the outcomes of a reconstruction protocol for patients who require irradiation after tissue expander/implant reconstruction. The charts of all patients who underwent immediate tissue expander/implant reconstruction at Memorial Sloan-Kettering Cancer Center between January of 1995 and June of 2001 and who had not previously undergone irradiation were retrospectively reviewed. A subgroup of patients who required chest wall irradiation after mastectomy and reconstruction was identified. Those patients were treated according to the following treatment algorithm: (1) reconstruction with tissue expander placement at the time of mastectomy , (2) tissue expansion during postoperative chemotherapy, (3) exchange of the tissue expander for a permanent implant approximately 4 weeks after the completion of chemotherapy, and (4) chest wall irradiation beginning 4 weeks after the exchange. All irradiated patients with at least 1 year of follow-up monitoring after the completion of radiotherapy were evaluated with respect to aesthetic outcomes, capsular contracture, and patient satisfaction. A control group of nonirradiated patients was randomly selected from the cohort of patients treated during the study period. During the 5-year study period, a total of 687 patients underwent immediate reconstruction with tissue expanders. Eighty-one patients underwent postoperative irradiation after placement of the final implant. A total of 68 patients who received postoperative chest wall irradiation underwent at least 1 year of follow-up monitoring after the completion of radiotherapy, with a mean follow-up period of 34 months. Seventy-five nonirradiated patients were evaluated as a control group. Overall, 68 percent of the irradiated patients developed capsular contracture, compared with 40 percent in the nonirradiated group (p = 0.025). Eighty percent of the irradiated patients demonstrated acceptable (good to excellent) aesthetic results, compared with 88 percent in the nonirradiated group (p = not significant). Sixty-seven percent of the irradiated patients were satisfied with their reconstructions, compared with 88 percent of the nonirradiated patients (p = 0.004). Seventy-two percent of the irradiated patients stated that they would choose the same form of reconstruction again, compared with 85 percent of the nonirradiated patients. The results of this study suggest that tissue expander/implant reconstruction is an acceptable surgical option even when followed by postoperative radiotherapy and should be considered in the reconstruction algorithm for all patients, particularly those who may not be candidates for autogenous reconstruction.

Entities:  

Mesh:

Year:  2004        PMID: 15108879     DOI: 10.1097/01.prs.0000105689.84930.e5

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  59 in total

1.  Fibrotic changes after postmastectomy radiotherapy and reconstructive surgery in breast cancer. A retrospective analysis in 109 patients.

Authors:  Johannes Classen; Sibille Nitzsche; Diethelm Wallwiener; Peter Kristen; Rainer Souchon; Michael Bamberg; Sara Brucker
Journal:  Strahlenther Onkol       Date:  2010-11-08       Impact factor: 3.621

Review 2.  Breast reconstruction following conservative mastectomies: predictors of complications and outcomes.

Authors:  Sophocles H Voineskos; Simon G Frank; Peter G Cordeiro
Journal:  Gland Surg       Date:  2015-12

3.  Preoperative digital mammography imaging in conservative mastectomy and immediate reconstruction.

Authors:  Alberto Rancati; Claudio Angrigiani; Dennis Hammond; Maurizio Nava; Eduardo Gonzalez; Roman Rostagno; Gustavo Gercovich
Journal:  Gland Surg       Date:  2016-02

4.  Therapeutic effects of cytoprotective agent on breast reconstruction after breast cancer surgery.

Authors:  Xinjia He; Lihua Wang; Wei Li; Zhuang Yu; Xingang Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 5.  Is there any argument for delayed breast reconstruction after total mastectomy?

Authors:  Michael J Greenall
Journal:  Ann R Coll Surg Engl       Date:  2007-11       Impact factor: 1.891

6.  Cost-Effectiveness Analysis of Breast Reconstruction Options in the Setting of Postmastectomy Radiotherapy Using the BREAST-Q.

Authors:  Shantanu N Razdan; Peter G Cordeiro; Claudia R Albornoz; Teresa Ro; Wess A Cohen; Babak J Mehrara; Colleen M McCarthy; Joseph J Disa; Andrea L Pusic; Evan Matros
Journal:  Plast Reconstr Surg       Date:  2016-03       Impact factor: 4.730

7.  Oncoplastic breast surgery: a global perspective on practice, availability, and training.

Authors:  Peter L Malycha; Ian R Gough; Marko Margaritoni; S V S Deo; Kerstin Sandelin; Ines Buccimazza; Gaurav Agarwal
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 8.  Developing a theoretical framework to illustrate associations among patient satisfaction, body image and quality of life for women undergoing breast reconstruction.

Authors:  Michelle Cororve Fingeret; Summer W Nipomnick; Melissa A Crosby; Gregory P Reece
Journal:  Cancer Treat Rev       Date:  2013-02-04       Impact factor: 12.111

9.  Differences in breast aesthetic outcomes due to radiation: A validated, quantitative analysis of expander-implant reconstruction.

Authors:  Lauren M Mioton; Jessica Gaido; William Small; Neil A Fine; John Y Kim
Journal:  Can J Plast Surg       Date:  2013

Review 10.  Recent advances in the surgical care of breast cancer patients.

Authors:  Alessandra Mascaro; Massimo Farina; Raffaella Gigli; Carlo E Vitelli; Lucio Fortunato
Journal:  World J Surg Oncol       Date:  2010-01-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.